Masayuki Isaji

2.0k citations
47 papers · 1.7k indexed · h-index 21

Masayuki Isaji

45 papers receiving 1.7k citations

Peers

Masayuki Isaji
Comparison fields: 5 of 102
  • Endocrinology, Diabetes and Metabolism 798
  • Surgery 534
  • Nephrology 81
  • Pharmacology 169
  • Molecular Biology 677
Replace Uday Saxena with:
Uday Saxena United States
Tomoko Tanaka Japan
Doina Popov Romania
Peng Yue United States
Francesc González‐Sastre Spain
E. Schleicher Germany
Bo Ding China
Jianguo Jin United States
Yukihiko Ueda Japan
Masayuki Isaji relative to Uday Saxena United States Uday Saxena's profile →
Citations per field
00.5×1.5×2.4×
Uday Saxena · 1×
Citations per year

Countries citing papers authored by Masayuki Isaji

Since Specialization
Citations

This map shows the geographic impact of Masayuki Isaji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masayuki Isaji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masayuki Isaji more than expected).

Fields of papers citing papers by Masayuki Isaji

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masayuki Isaji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masayuki Isaji. The network helps show where Masayuki Isaji may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Masayuki Isaji, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Masayuki Isaji Line = papers co-authored together Masayuki Isaji links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 201268
2 201216
3 201185
4 20103
5 2008190
6 200820
7 200826
8 200817
9 2006222
10 200571
11 200532
12 200513
13 2004159
14
KGT-1251, a novel selective SGLT2 inhibitor, has anti-diabetic effect in diabetic rodent models
20011
15 200023
16 199818
17 199618
18 199621
19 199519
20 19938

About Masayuki Isaji

Masayuki Isaji is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology and Endocrine and Autonomic Systems, having authored 47 papers that have together received 1.7k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (11 papers), Pancreatic function and diabetes (9 papers), Metabolism, Diabetes, and Cancer (5 papers), Mast cells and histamine (5 papers), Parkinson's Disease Mechanisms and Treatments (4 papers), Diet, Metabolism, and Disease (4 papers), Adipokines, Inflammation, and Metabolic Diseases (3 papers) and Protease and Inhibitor Mechanisms (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (798 citations), Surgery (534 citations) and Nephrology (81 citations). Masayuki Isaji has collaborated with scholars based in Japan, United States and Brazil. Frequent co-authors include Kenji Katsuno, Yoshikazu Fujimori, Hideki Fujikura, Fumiaki Itoh, Hiroshi Miyata, Masahiro Hiratochi, Yukiko Takemura, Jun Naito, Yoshimitsu Komatsu and Misao Nakajoh. Their work appears in journals such as The FASEB Journal, Kidney International and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026